Pacer Advisors Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 43.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 684,289 shares of the specialty pharmaceutical company’s stock after buying an additional 206,243 shares during the quarter. Pacer Advisors Inc. owned about 1.07% of Jazz Pharmaceuticals worth $84,831,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. US Bancorp DE grew its stake in Jazz Pharmaceuticals by 13.3% during the 1st quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 322 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $547,000. Aviva PLC lifted its position in Jazz Pharmaceuticals by 87.1% during the 1st quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock worth $6,228,000 after acquiring an additional 18,628 shares during the period. Allianz Asset Management GmbH lifted its position in Jazz Pharmaceuticals by 118.2% during the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after acquiring an additional 6,571 shares during the period. Finally, Vanguard Group Inc. lifted its position in Jazz Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock worth $872,164,000 after acquiring an additional 57,949 shares during the period. Hedge funds and other institutional investors own 88.15% of the company’s stock.

Jazz Pharmaceuticals Trading Down 0.8 %

Shares of JAZZ traded down $1.12 during mid-day trading on Tuesday, hitting $131.24. The company’s stock had a trading volume of 91,113 shares, compared to its average volume of 519,570. The company has a quick ratio of 2.49, a current ratio of 3.18 and a debt-to-equity ratio of 1.61. The firm has a 50-day simple moving average of $134.71 and a 200 day simple moving average of $134.86. Jazz Pharmaceuticals plc has a 1-year low of $120.64 and a 1-year high of $160.96.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $3.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.68 by $0.15. The firm had revenue of $957.32 million during the quarter, compared to analysts’ expectations of $952.44 million. Jazz Pharmaceuticals had a positive return on equity of 24.47% and a negative net margin of 2.30%. On average, research analysts expect that Jazz Pharmaceuticals plc will post 15.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $226.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, August 7th. StockNews.com assumed coverage on Jazz Pharmaceuticals in a research report on Thursday, August 17th. They set a “strong-buy” rating for the company. Bank of America increased their price objective on Jazz Pharmaceuticals from $204.00 to $217.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $204.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, August 11th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $206.67.

Insider Buying and Selling

In related news, Director Rick E. Winningham sold 1,241 shares of Jazz Pharmaceuticals stock in a transaction on Monday, August 14th. The stock was sold at an average price of $138.16, for a total transaction of $171,456.56. Following the completion of the transaction, the director now directly owns 10,444 shares of the company’s stock, valued at $1,442,943.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 750 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $139.59, for a total transaction of $104,692.50. Following the completion of the transaction, the executive vice president now owns 30,686 shares of the company’s stock, valued at $4,283,458.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rick E. Winningham sold 1,241 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $138.16, for a total value of $171,456.56. Following the transaction, the director now directly owns 10,444 shares of the company’s stock, valued at approximately $1,442,943.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,791 shares of company stock valued at $534,726. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.